iRhythm Technologies, Inc. (IRTC) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $224.2 million, up 20.1% year-over-year, marking the seventh consecutive quarter of over 20% growth.

Gross Margin: 72.8%, an increase of 160 basis points year-over-year, driven by operational efficiencies and higher volumes.

Adjusted Operating Expenses: $145 million, essentially flat compared to the previous year, reflecting disciplined cost management.

GAAP Net Loss: $0.4 million ($0.01 per diluted share), significantly improved from a loss of $14.2 million ($0.44 per diluted share) in Q2 2025.

Adjusted Net Income: $19.3 million ($0.58 per diluted share), compared to an adjusted net loss of $10.2 million in the prior year.

Adjusted EBITDA: $43.3 million (19.3% of revenue), up over 1,000 basis points year-over-year.

Free Cash Flow: Positive $37.5 million, a record for the company.

Cash Position: $591.3 million in cash equivalents and marketable securities.

2Strategic Updates and Business Highlights

Acquisition of VitalConnect: Announced acquisition to enhance capabilities in mobile cardiac telemetry (MCT) and expand the product portfolio. VitalConnect's technology supports various cardiac monitoring modalities and is FDA-cleared for continuous patient monitoring.

Growth in Innovative Channels: Continued strong momentum in innovative channels, particularly in primary care and value-based care partnerships.

Predictive Arrhythmia Solutions: Progress made with partnerships to enhance early diagnosis and intervention for arrhythmias.

International Expansion: Continued commercialization efforts in the U.K., Netherlands, and Japan, with a focus on building clinical evidence and market presence.

Regulatory Updates: Positive developments regarding reimbursement policies and FDA clearance of a third-generation algorithm expected to enhance productivity and reduce costs.

3Forward Guidance and Outlook

Full-Year 2026 Revenue Guidance: Raised to $880 million-$890 million, reflecting 18%-19% year-over-year growth.

Q3 2026 Revenue Guidance: Expected to be in the range of $221 million-$223 million.

Adjusted EBITDA Margin Guidance: Raised to 13%-14% for the full year, with Q3 expected at 12%-13%.

Long-Term Growth: Confidence in achieving a 15% adjusted EBITDA margin in 2027, bolstered by the VitalConnect acquisition.

4Bad News, Challenges, or Points of Concern

FDA Warning Letter: The company is still under an FDA warning letter and is working through the agency's review process.

Litigation Settlement: A $50 million settlement with Baxter and its subsidiaries was reached, which may impact cash flow.

Cybersecurity Incident: Acknowledged unauthorized activity in third-party-hosted applications, though no material impact on operations or financial results was reported.

Market Competition: Concerns about competitive pressures in the MCT space, particularly with multiple players in the market.

5Notable Q&A Insights

VitalConnect Integration: Management emphasized the importance of effectively integrating VitalConnect into the commercial team and scaling operations to meet expected demand.

MCT Strategy: The dual product strategy in the MCT category was reiterated, with VitalConnect expected to complement existing offerings rather than cannibalize them.

Direct-to-Patient Marketing: Early indicators from direct-to-patient initiatives are promising, with plans for expansion based on initial results.

Innovative Channel Growth: Continued optimism about the innovative channel's potential, with new partnerships contributing to growth.

Regulatory Confidence: Management expressed confidence in navigating regulatory processes related to the acquisition and product clearances. Overall, iRhythm Technologies reported strong financial performance in Q2 2026, driven by robust demand and strategic initiatives, while also addressing challenges related to regulatory compliance and market competition. The acquisition of VitalConnect is seen as a pivotal move to enhance their product offerings and market position.